
Advanced Enzyme (ADVENZYMES) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.9B
Gross Profit
1.4B
73.08%
Operating Income
468.1M
25.18%
Net Income
404.4M
21.75%
EPS (Diluted)
₹3.57
Balance Sheet Metrics
Total Assets
16.2B
Total Liabilities
1.5B
Shareholders Equity
14.7B
Debt to Equity
0.10
Cash Flow Metrics
Revenue & Profitability Trend
Advanced Enzyme Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 6.4B | 6.2B | 5.4B | 5.3B | 5.0B |
Cost of Goods Sold | 1.6B | 1.6B | 1.4B | 1.2B | 1.1B |
Gross Profit | 4.7B | 4.6B | 4.0B | 4.1B | 3.9B |
Gross Margin % | 74.1% | 74.4% | 73.6% | 77.4% | 78.9% |
Operating Expenses | |||||
Research & Development | 8.8M | 8.1M | 8.1M | 6.5M | 6.3M |
Selling, General & Administrative | 426.1M | 397.2M | 379.1M | 354.8M | 243.8M |
Other Operating Expenses | 816.3M | 793.6M | 752.4M | 619.0M | 475.8M |
Total Operating Expenses | 1.3B | 1.2B | 1.1B | 980.3M | 725.8M |
Operating Income | 1.6B | 1.7B | 1.4B | 1.7B | 2.1B |
Operating Margin % | 25.2% | 27.7% | 25.6% | 31.9% | 41.9% |
Non-Operating Items | |||||
Interest Income | 198.1M | 133.3M | 94.8M | 4.0M | 5.8M |
Interest Expense | 35.6M | 29.3M | 24.2M | 18.0M | 16.1M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.9B | 1.9B | 1.4B | 1.7B | 2.1B |
Income Tax | 533.9M | 508.7M | 365.2M | 472.6M | 588.4M |
Effective Tax Rate % | 28.5% | 27.1% | 26.0% | 27.6% | 28.0% |
Net Income | 1.3B | 1.4B | 1.0B | 1.2B | 1.5B |
Net Margin % | 21.0% | 22.0% | 19.2% | 23.4% | 30.2% |
Key Metrics | |||||
EBITDA | 2.2B | 2.3B | 1.9B | 2.1B | 2.4B |
EPS (Basic) | ₹11.72 | ₹11.92 | ₹9.45 | ₹10.70 | ₹13.06 |
EPS (Diluted) | ₹11.71 | ₹11.92 | ₹9.45 | ₹10.68 | ₹13.04 |
Basic Shares Outstanding | 111852146 | 111824075 | 111815999 | 111777150 | 111696500 |
Diluted Shares Outstanding | 111852146 | 111824075 | 111815999 | 111777150 | 111696500 |
Income Statement Trend
Advanced Enzyme Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 942.2M | 1.1B | 964.2M | 2.7B | 1.9B |
Short-term Investments | 5.0B | 4.3B | 3.9B | 1.1B | 1.3B |
Accounts Receivable | 1.2B | 985.7M | 1.0B | 882.1M | 862.7M |
Inventory | 1.6B | 1.5B | 1.2B | 1.2B | 938.8M |
Other Current Assets | 13.7M | 17.3M | 9.7M | 4.7M | 4.0M |
Total Current Assets | 8.8B | 8.1B | 7.2B | 6.0B | 5.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.9B | 2.8B | 2.7B | 2.6B | 183.5M |
Goodwill | 7.2B | 7.1B | 7.0B | 6.6B | 6.5B |
Intangible Assets | 523.1M | 582.9M | 608.8M | 663.1M | 746.7M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 300.0K | 300.0K | 850.0K | 840.0K | 520.0K |
Total Non-Current Assets | 7.4B | 7.3B | 7.0B | 6.7B | 6.4B |
Total Assets | 16.2B | 15.4B | 14.2B | 12.7B | 11.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 172.0M | 157.6M | 242.2M | 179.0M | 152.2M |
Short-term Debt | 184.3M | 244.9M | 111.2M | 82.5M | 141.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 85.3M | 135.9M | 105.2M | 97.8M | 130.1M |
Total Current Liabilities | 967.6M | 1.1B | 775.7M | 604.2M | 675.6M |
Non-Current Liabilities | |||||
Long-term Debt | 209.2M | 228.2M | 223.8M | 264.8M | 137.9M |
Deferred Tax Liabilities | 336.3M | 343.2M | 372.3M | 392.5M | 408.5M |
Other Non-Current Liabilities | - | - | - | - | -10.0K |
Total Non-Current Liabilities | 559.2M | 580.3M | 601.1M | 668.0M | 560.0M |
Total Liabilities | 1.5B | 1.6B | 1.4B | 1.3B | 1.2B |
Equity | |||||
Common Stock | 223.8M | 223.6M | 223.6M | 223.6M | 223.5M |
Retained Earnings | 11.5B | 10.8B | 10.0B | 9.1B | 8.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 14.7B | 13.7B | 12.8B | 11.4B | 10.3B |
Key Metrics | |||||
Total Debt | 393.5M | 473.1M | 335.0M | 347.3M | 279.6M |
Working Capital | 7.8B | 7.0B | 6.4B | 5.4B | 4.5B |
Balance Sheet Composition
Advanced Enzyme Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.9B | 1.9B | 1.4B | 1.7B | 2.1B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 34.5M | 30.3M | 0 | 0 | 3.8M |
Working Capital Changes | -144.8M | -263.3M | -55.5M | -296.6M | -155.3M |
Operating Cash Flow | 1.7B | 1.5B | 1.3B | 1.4B | 1.9B |
Investing Activities | |||||
Capital Expenditures | -332.8M | -421.6M | -378.5M | -268.2M | -193.0M |
Acquisitions | - | - | - | 0 | -16.3M |
Investment Purchases | -647.9M | -304.3M | -2.7B | -2.4M | -58.9M |
Investment Sales | - | - | 0 | 221.0M | - |
Investing Cash Flow | -980.7M | -725.9M | -3.1B | -49.6M | -268.1M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -590.3M | -567.1M | -125.4M | -118.6M | -79.8M |
Debt Issuance | 22.3M | - | 0 | 6.7M | 80.2M |
Debt Repayment | -58.1M | -6.5M | -3.2M | -23.2M | -236.9M |
Financing Cash Flow | -680.4M | -502.6M | -169.0M | -406.9M | -265.4M |
Free Cash Flow | 1.1B | 940.6M | 1.0B | 941.2M | 1.4B |
Net Change in Cash | 41.4M | 316.4M | -1.9B | 964.7M | 1.4B |
Cash Flow Trend
Advanced Enzyme Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.13
Forward P/E
24.67
Price to Book
2.42
Price to Sales
5.14
PEG Ratio
1.47
Profitability Ratios
Profit Margin
20.48%
Operating Margin
25.18%
Return on Equity
8.93%
Return on Assets
8.09%
Financial Health
Current Ratio
9.09
Debt to Equity
2.68
Beta
0.37
Per Share Data
EPS (TTM)
₹12.22
Book Value per Share
₹127.00
Revenue per Share
₹59.77
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
advenzymes | 34.4B | 25.13 | 2.42 | 8.93% | 20.48% | 2.68 |
Asian Paints | 2.4T | 67.58 | 12.50 | 18.28% | 10.63% | 11.42 |
Pidilite Industries | 1.6T | 71.94 | 16.09 | 20.85% | 16.16% | 4.56 |
Tanfac Industries | 46.6B | 48.54 | 14.95 | 32.50% | 15.83% | 13.28 |
Kingfa Science | 46.2B | 30.12 | 6.35 | 20.98% | 8.58% | 5.90 |
Grauer & Weil | 42.1B | 26.73 | 4.48 | 16.73% | 13.35% | 1.26 |
Financial data is updated regularly. All figures are in the company's reporting currency.